New study aims to uncover hidden risks of cancer immunotherapy on the liver
NCT ID NCT04476563
First seen Sep 30, 2025 · Last updated May 24, 2026 · Updated 33 times
Summary
This study observes 160 people who develop liver injury from checkpoint inhibitor cancer drugs. Researchers aim to find out how common this side effect is and what makes some people more at risk. They will also look for blood markers that could help diagnose the condition earlier. No new treatments are being tested.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IMMUNE-MEDIATED HEPATITIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Nottingham
RECRUITINGNottingham, NG72RD, United Kingdom
Contact
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.